GlassScriptPhysician profile
Mona V Mangat
NPI 1972671824
$7,693.69
in general payments reported to CMS, 2019-2025
35 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $450 · 2021: $1,165 · 2022: $1,423 · 2023: $1,188 · 2024: $1,178 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,707.84 |
| Education | $286.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,425.91 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $905.55 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $898.06 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $830.43 | 2019-2025 | Dupixent |
| Genzyme Corporation | $521.87 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $446.25 | 2019-2025 | |
| Amgen INC. | $434.54 | 2021-2025 | Tezspire |
| Pfizer INC. | $390.25 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $295.27 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Kaleo, INC. | $178.82 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $134.75 | 2019-2025 | Xolair |
| Abbvie INC. | $132.50 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $116.94 | 2022-2023 | |
| Optinose US, INC. | $113.55 | 2019-2025 | |
| Ionis Pharmaceuticals, INC. | $89.87 | 2025 | Dawnzera |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $85.05 | 2021-2024 | Orladeyo |
| Covis Pharma Gmbh | $82.62 | 2021 | |
| Incyte Corporation | $73.08 | 2021-2022 | |
| Shire North American Group INC | $72.66 | 2019 | |
| Galderma Laboratories, L.P. | $56.28 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $53.43 | 2020-2025 | Ruconest |
| Octapharma USA, INC. | $53.26 | 2021 | |
| Hikma Pharmaceuticals USA | $45.17 | 2023-2024 | Ryaltris |
| Azurity Pharmaceuticals, INC. | $40.83 | 2025 | Alvesco |
| Teva Pharmaceuticals USA, INC. | $26.97 | 2021 | |
| Tersera Therapeutics LLC | $26.10 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $24.19 | 2025 | Neffy |
| Leo Pharma INC. | $22.49 | 2022 | |
| Merck Sharp & Dohme LLC | $20.69 | 2021 | |
| Gc Biopharma USA, INC. | $20.64 | 2025 | Alyglo |
| Aimmune Therapeutics, INC. | $19.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.22 | 2021 | |
| Phadia US INC. | $18.08 | 2022 | |
| Horizon Therapeutics Plc | $17.99 | 2021 | |
| Organon LLC | $1.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Mangat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.